Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Bone

• Publication date

  1996-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/8756-3282(95)00436-XPMID 8833208
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rationale for the use of alendronate in osteoporosis

  2005cited by this paper
• Bisphosphonates in osteoporosis: An introduction

  2005cited by this paper
• Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis.

  1996cited by this paper
• Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling.

  1995cited by this paper
• Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis.

  1995cited by this paper
• Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment.

  1994cited by this paper
• Slow-Release Sodium Fluoride in the Management of Postmenopausal Osteoporosis

  1994cited by this paper
• The bone‐remodeling transient: Implications for the interpretation of clinical studies of bone mass change

  1994cited by this paper
• Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group.

  1993cited by this paper
• Long‐term fracture prediction by bone mineral assessed at different skeletal sites

  1993cited by this paper
• Bisphosphonates in the treatment of metabolic bone diseases.

  1993cited by this paper
• The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates.

  1993cited by this paper
• Cyclic etidronate: has the rose lost its bloom?

  1993cited by this paper
• Comparison of the therapeutic potencies of two bisphosphonates

  1992cited by this paper
• The effect of overlying calcification on lumbar bone densitometry

  1992cited by this paper
• Effects of 4‐amino‐1‐hydroxybutylidene bisphosphonate on bone biomechanics in rats

  1992cited by this paper
• Prevention and treatment of osteoporosis: a review of current modalities.

  1992cited by this paper
• The prevention and treatment of osteoporosis.

  1992cited by this paper
• The bisphosphonate, alendronate, prevents bone loss in ovariectomized baboons

  1992cited by this paper
• Bone mineral density in the proximal femur and hip fracture type in the elderly

  1992cited by this paper
• Age‐related decrements in bone mineral density in women over 65

  1992cited by this paper
• The bisphosphonate alendronate (MK‐217) inhibits bone loss due to ovariectomy in rats

  1991cited by this paper
• Pre-existing fractures and bone mass predict vertebral fracture incidence in women.

  1991cited by this paper
• Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.

  1990cited by this paper
• Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis.

  1990cited by this paper
• Effect of radiographic abnormalities on rate of bone loss from the spine

  1990cited by this paper
• The impact of osteophytic and vascular calcifications on vertebral mineral density measurements in men.

  1990cited by this paper
• Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis.

  1988cited by this paper
• Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat

  1986cited by this paper
• Testing the statistical certainty of a response to increasing doses of a drug.

  1985cited by this paper

• Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.

  2025cites this paper
• Screening for Osteoporosis to Prevent Fractures: A Systematic Evidence Review for the US Preventive Services Task Force.

  2025cites this paper
• Improvement of bone mineral density and new vertebral fractures during 8 years of TNF-α inhibition in patients with axial spondyloarthritis.

  2024cites this paper
• Cardiovascular Safety of Romosozumab Compared to Commonly Used Anti-osteoporosis Medications in Postmenopausal Osteoporosis: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials

  2024cites this paper
• The Bone, Exercise, Alendronate, and Caloric Restriction (BEACON) trial design and methods.

  2024cites this paper
• Meta-analysis of placebo-arm dropouts in osteoporosis randomized-controlled trials and implications for nocebo-associated discontinuation of anti-osteoporotic drugs in clinical practice

  2023influential citation
• Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools

  2023cites this paper
• Exercise Prescription for Osteoporosis: Back to Basics.

  2022cites this paper
• Effects of Bisphosphonate on Osteocyte Proliferation and Bone Formation in Patients with Diabetic Osteoporosis

  2022cites this paper
• Monitoring the reduction and maintenance of periprosthetic bone tissue in cementless primary hip endoprosthesis with alendronate therapy

  2021cites this paper
• The Effects of Osteoporotic and Non-osteoporotic Medications on Fracture Risk and Bone Mineral Density

  2021cites this paper
• Osteoporosis Therapy: Mechanistic Antiresorptives

  2021cites this paper
• THE EFFECT OF SODIUM ALENDRONATE GEL ON OSSEOINTEGRATION OF SUBMERGED DENTAL IMPLANTS

  2020cites this paper
• Drugs for the Treatment and Prevention of Osteoporosis in Postmenopausal Women

  2019cites this paper
• Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review

  2019cites this paper
• Predictive factors for the efficacy of denosumab in postmenopausal Japanese women with non-metastatic breast cancer receiving adjuvant aromatase inhibitors: a combined analysis of two prospective clinical trials

  2019cites this paper
• Comparative Efficacy of Alendronate upon Vertebral Bone Mineral Density and Fracture Rates in East Asians Versus Non-East Asians with Postmenopausal Osteoporosis: A Systematic Review and Meta-Analysis

  2018cites this paper
• Upper Gastrointestinal Tract Safety Profile of Alendronate

  2017cites this paper
• Upper gastrointestinal safety and tolerability of oral alendronate: A meta-analysis.

  2016cites this paper
• Efficacy and Safety of Bisphosphonates for Osteoporosis or Osteopenia in Cardiac Transplant Patients: A Meta-Analysis.

  2015cites this paper
• BAP Immunoenzymetric Assay For the quantitative measurement of Bone-specific Alkaline Phosphatase ( BAP ) in human serum

  2015influential citation
• Bone augmentation using a new injectable bone graft substitute by combining calcium phosphate and bisphosphonate as composite—an animal model

  2015cites this paper
• Bisphosphonate treatment of type I diabetic mice prevents early bone loss but accentuates suppression of bone formation

  2015cites this paper
• Sporadic Acquired and Genetic Disorders of Bone

  2014cites this paper
• Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis

  2014cites this paper
• Differing effects of denosumab and alendronate on cortical and trabecular bone.

  2014cites this paper
• Systematic analysis of bisphosphonate intervention on periprosthetic BMD as a function of stem design.

  2014cites this paper
• Osteoporosis Society of the Philippines Foundation , President Vice President

  2013cites this paper
• Persistence with weekly and monthly bisphosphonates among postmenopausal women: analysis of a US pharmacy claims administrative database

  2013cites this paper
• A critical review of brand and generic alendronate for the treatment of osteoporosis

  2013cites this paper
• The impact of alendronate on bone mineral density of osteoporotic patients.

  2013cites this paper
• Micro-morphological properties of osteons reveal changes in cortical bone stability during aging, osteoporosis, and bisphosphonate treatment in women

  2013cites this paper
• Alendronate sodium hydrate (oral jelly) for the treatment of osteoporosis: review of a novel, easy to swallow formulation

  2013cites this paper
• Increased numbers of nonattached osteoclasts after long-term zoledronic acid therapy in mice.

  2012cites this paper
• Alendronate

  2012influential citation
• Rheumatoid arthritis: biologicals and bone

  2011cites this paper
• ALENDRONATE A PROMISING / MULTI ASPECT DRUG IN THE MANAGEMENT OF OSTOEOPOROSIS

  2011cites this paper
• Zoledronate, ibandronate and clodronate enhance osteoblast differentiation in a dose dependent manner--a quantitative in vitro gene expression analysis of Dlx5, Runx2, OCN, MSX1 and MSX2.

  2011cites this paper
• Comparison of the Effects of Local Application of Hydroxyapatite Graft Soaked with Alendronate Solution and Pure Hydroxyapatite Graft in the Mandible of Ovariectomized Rats

  2011cites this paper
• Comparison of the Effects of Ossein-Hydroxyapatite Complex and Calcium Carbonate on Bone Metabolism in Women with Senile Osteoporosis

  2011cites this paper
• Comparative Effectiveness of Alendronate and Risedronate on the Risk of Non-Vertebral Fractures in Older Women: An Instrumental Variables Approach: A Dissertation

  2011cites this paper
• Alendronate Reduces Periprosthetic Bone Loss after Uncemented Primary Total Hip Arthroplasty — A 5-Year Follow-up of 16 Patients

  2010cites this paper
• 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary

  2010cites this paper
• The impact of bisphosphonates on the osteoblast proliferation and Collagen gene expression in vitro

  2010cites this paper
• Prevention of Hip Fractures in Long‐Term Care: Relevance of Community‐Derived Data

  2010cites this paper
• Effects of alendronate on bone healing after tooth extraction in rats.

  2010cites this paper
• Gastroresistant microparticles containing sodium alendronate prevent the bone loss in ovariectomized rats.

  2010cites this paper
• [Austrian guidance for the pharmacological treatment of osteoporosis in postmenopausal women--update 2009].

  2009cites this paper
• A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis.

  2009cites this paper
• Assessment of vertebral fracture risk and therapeutic effects of alendronate in postmenopausal women using a quantitative computed tomography-based nonlinear finite element method

  2009cites this paper
• Synthesis and Assessment of 99mTc Chelate-Conjugated Alendronate for Development of Specific Radiopharmaceuticals

  2009cites this paper
• Quantitative computed tomography (QCT) of the forearm using general purpose spiral whole-body CT scanners: accuracy, precision and comparison with dual-energy X-ray absorptiometry (DXA).

  2009cites this paper
• Prevention of New Vertebral Fractures after Treatment with Risedronate, Alendronate or Calcium Carbonate in Patients with Osteoporotic Compression Fracture Treated with Cement Augmentation

  2009cites this paper
• Microdamage accumulation in the monkey vertebra does not occur when bone turnover is suppressed by 50% or less with estrogen or raloxifene

  2009cites this paper
• Österreichischer Leitfaden zur medikamentösen Therapie der postmenopausalen Osteoporose – Update 2009

  2009cites this paper
• Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.

  2008cites this paper
• Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.

  2008cites this paper
• Effect of Homocysteine and Protective Role of Trimethylglyc ine on the Structure of Tibia in Growing Albino Rats: Histological and Biochemical Study

  2008cites this paper
• Biological options to enhance periprosthetic bone mass.

  2007cites this paper
• 骨粗鬆症治療薬アレンドロネート週1回投与製剤（フォサマック錠35 mg／ボナロン錠35 mg）の薬理学特性と臨床効果

  2007cites this paper
• Fracture Callus Under Anti-resorptive Agent Treatment Evaluated by pQCT

  2007cites this paper
• [Pharmacological and clinical profile of once weekly alendronate for the treatment of osteoporosis (Fosamac 35 mg/Bonalon 35 mg)].

  2007cites this paper
• Alendronate therapy in cyclosporine-induced alveolar bone loss in rats.

  2007cites this paper
• 8.16 – Fosamax

  2007cites this paper
• Pelvic insufficiency fracture associated with severe suppression of bone turnover by alendronate therapy

  2007cites this paper
• The Ideal Drug for Treatment of Osteoporosis

  2007cites this paper
• Kidney function predicts the rate of bone loss in older individuals: the Cardiovascular Health Study.

  2006cites this paper
• Canadian Agency for Drugs and Technologies in Health Bisphosphonates for the Primary and Secondary Prevention of Osteoporotic Fractures in Postmenopausal Women : A Meta-Analysis

  2006cites this paper
• Efficacy and safety of oral alendronate treatment in children and adolescents with osteoporosis.

  2006cites this paper
• Biomechanics

  2006cites this paper
• Bisphosphonate therapy for bone loss in patients with osteoporosis and periodontal disease: clinical perspectives and review of the literature.

  2006cites this paper
• Predictions on preserving bone mass in knee arthroplasty with bisphosphonates.

  2006cites this paper
• How Much Calcium Is in Your Drinking Water? A Survey of Calcium Concentrations in Bottled and Tap Water and Their Significance for Medical Treatment and Drug Administration

  2006cites this paper
• Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study

  2005cites this paper
• Efficacy of different dosing schedules of etidronate for stress shielding after cementless total hip arthroplasty

  2005cites this paper
• The influence of alendronate on bone formation after autogenous free bone grafting in rats.

  2005cites this paper
• Calcium Requirements During Treatment of Osteoporosis in Women

  2005cites this paper
• Compliance with osteoporosis medications.

  2005cites this paper
• Upper gastrointestinal tract safety of daily oral risedronate in patients taking NSAIDs: a randomized, double-blind, placebo-controlled trial.

  2005cites this paper
• The Role of Calcium in Osteoporosis Drug Therapy

  2005cites this paper
• Lumbar bone mineral density in very long-term renal transplant recipients: Impact of circulating sex hormones

  2005influential citation
• Alendronate treatment for osteoporosis: A review of the clinical evidence

  2005cites this paper
• Effects of Alendronate and Calcitonin on Bone Mineral Density in Postmenopausal Osteoporotic Women. An Observational Study

  2005cites this paper
• ROL' I MESTO BISFOSFONATOV V PROFILAKTIKE I LEChENII OSTEOPOROZA. 10-LETNIY OPYT PRIMENENIYa ALENDRONATA (FOSAMAKSA)Obzor literatury

  2005cites this paper
• The use of bisphosphonates in the treatment of osteoporosis

  2005cites this paper
• Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort Study.

  2004cites this paper
• The Role of Clinical Pharmacology and of Pharmacokinetics in The Development of Alendronate - A Bone Resorption Inhibitor

  2004cites this paper
• Efficacy of Intermittent Low Dose Alendronate in Thai Postmenopausal Osteoporosis

  2004cites this paper
• Effects of discontinuation as well as intervention of cyclic therapy with etidronate on bone remodeling after cementless total hip arthroplasty.

  2004cites this paper
• Effect of alendronate on bone density and bone markers in postmenopausal osteoporosis

  2004cites this paper
• National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section

  2004cites this paper
• The Impact of Fragility Fracture on Health-Related Quality of Life

  2004cites this paper
• Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study

  2004cites this paper
• Nitrogen-containing bisphosphonate mechanism of action.

  2004cites this paper
• Age- and BMD-related differences in biochemical markers of bone metabolism in rural and urban women from Lublin Region, Poland.

  2004cites this paper
• Prevention and Treatment of Osteoporosis in Postmenopausal Women

  2004cites this paper
• Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study

  2004cites this paper
• Decimal point--osteoporosis therapy at the 10-year mark.

  2004cites this paper
• Prevention and Treatment of Postmenopausal Osteoporosis

  2003cites this paper
• The Facts of Hormone Therapy for Menopausal Women

  2003cites this paper